Article
Antidiabetic sulfonylureas and cAMP cooperatively activate Epac2A.
Science signaling - 22 Oct 2013
Takahashi Toshimasa, Shibasaki Tadao, Takahashi Harumi, Sugawara Kenji, Ono Aika, Inoue Naoko, Furuya Toshio, Seino Susumu
Abstract excerpt
Sulfonylureas are widely used drugs for treating insulin deficiency in patients with type 2 diabetes. Sulfonylureas bind to the regulatory subunit of the pancreatic β cell potassium channel that controls insulin secretion. Sulfonylureas also bind to and activate Epac2A, a member of the Epac family of cyclic adenosine monophosphate (cAMP)-binding proteins that promote insulin secretion through activation of the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
